de Vitry A, Valois A, Weinborn M, Dupuy-de Fonclare A-L, Cuny J-F, Barbaud A, Schmutz J-L
Service de dermatologie, batiment Philippe-Canton, CHU, 6, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France.
Service de dermatologie, hôpital d'instruction des armées Legouest, 27, avenue de Plantières, 57070 Metz, France.
Ann Dermatol Venereol. 2014 Jun-Jul;141(6-7):441-5. doi: 10.1016/j.annder.2014.03.012. Epub 2014 Apr 8.
Acquired haemophilia A (AH) is an uncommon bleeding disorder that presents as multiple, disseminated spontaneous subcutaneous bleeds. Diagnosis may be made on the basis of prolonged activated partial thromboplastin time (aPTT). The severity of the disease is associated with the low risk of haemoglobin levels and with potential links with other diseases.
Two men were hospitalized for extensive and spontaneous subcutaneous hematoma. In both cases, the International Normalized Ratio (INR) was normal, but aPTT was 3 times higher than normal. Autoantibodies against coagulation factor VIII confirmed the diagnosis of AH. The patients received immunomodulatory treatment. In one patient, diffuse large B-cell lymphoma was discovered one year after successful treatment of AH.
AH may be revealed by areas of bruising, subutaneous haematomas mimicking erythema nodosum, and muscle pain. APTT results alone can prompt the biologist to screen for factor VIII inhibitors. Aside from the risk of fatal bleeding, in half of all cases, the prognosis is determined by associated disorders such as blood dyscrasias, solid tumours, autoimmune diseases, use of certain medicines and pregnancy. After treatment for bleeding complications, therapy focuses on restoring the coagulation time. The aim of immunomodulatory therapy is to stem production of autoantibodies against coagulation factor VIII.
AH must be considered rapidly in order to reduce the risk of bleeding emergencies and to screen for potential related diseases.
获得性血友病A(AH)是一种罕见的出血性疾病,表现为多发性、弥漫性自发性皮下出血。可根据活化部分凝血活酶时间(aPTT)延长进行诊断。该疾病的严重程度与血红蛋白水平低风险以及与其他疾病的潜在关联有关。
两名男性因广泛的自发性皮下血肿住院。在这两个病例中,国际标准化比值(INR)正常,但aPTT比正常高3倍。抗凝血因子VIII自身抗体确诊为AH。患者接受了免疫调节治疗。在一名患者中,AH成功治疗一年后发现弥漫性大B细胞淋巴瘤。
AH可能表现为瘀斑、类似结节性红斑的皮下血肿以及肌肉疼痛。仅aPTT结果就可促使生物学家筛查因子VIII抑制剂。除致命性出血风险外,在所有病例的一半中,预后由血液系统疾病、实体瘤、自身免疫性疾病、某些药物使用和妊娠等相关疾病决定。在治疗出血并发症后,治疗重点是恢复凝血时间。免疫调节治疗的目的是阻止针对凝血因子VIII的自身抗体产生。
必须迅速考虑AH,以降低出血紧急情况的风险并筛查潜在相关疾病。